Abstract: Objective  To systematically review the clinical efficacy and security of levetiracetam reducing the recurrence rate of febrile seizures. Methods  Databases such as PubMed， Cochrane Library， Embase， CBM， Wan fang Data， VIP and CNKI were searched  in levetiracetam as interventions in the treatment of febrile seizures from inception to March 20th， 2016. Literature screening， extracting data and evaluating methodological quality were independently performed by two reviewers. Metaanalysis was conducted using RevMan 5.2 software. Results  A total of 5 studies involving 475 patients were included. Metaanalysis showed that compared with conventional method of antifebrile， levetiracetam can significantly reduce the recurrence rate of febrile seizures than the conventional antifebrile method (RR=0.30， 95%CI［0.21，0.43］，P<0.01); but can not reduce the incidence rate of epilepsy (RR=1.11， 95%CI［0.26，4.79］，P=0.89); and can increase the incidence rate of adverse reactions (RR=4.36， 95%CI［1.01，18.76］，P=0.05). Conclusion  Levetiracetam can significantly reduce the recurrence rate of febrile seizures， and can not reduce the rate of epilepsy， but  increase the incidence of adverse reactions.

Key words: seizures, febrile, levetiracetam, evaluation studies, metaanalysis